- Home
- CHRS vs NOTE Comparison
CHRS vs NOTE Comparison
Compare CHRS & NOTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- NOTE
- Stock Information
- Founded
- CHRS 2010
- NOTE 2013
- Country
- CHRS United States
- NOTE United States
- Employees
- CHRS N/A
- NOTE N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- NOTE EDP Services
- Sector
- CHRS Health Care
- NOTE Technology
- Exchange
- CHRS Nasdaq
- NOTE Nasdaq
- Market Cap
- CHRS 191.3M
- NOTE 169.3M
- IPO Year
- CHRS 2014
- NOTE N/A
- Fundamental
- Price
- CHRS $1.32
- NOTE $1.37
- Analyst Decision
- CHRS Strong Buy
- NOTE Strong Buy
- Analyst Count
- CHRS 4
- NOTE 6
- Target Price
- CHRS $5.38
- NOTE $3.30
- AVG Volume (30 Days)
- CHRS 2.0M
- NOTE 3.8M
- Earning Date
- CHRS 03-12-2025
- NOTE 03-11-2025
- Dividend Yield
- CHRS N/A
- NOTE N/A
- EPS Growth
- CHRS N/A
- NOTE N/A
- EPS
- CHRS N/A
- NOTE N/A
- Revenue
- CHRS $304,340,000.00
- NOTE $125,062,000.00
- Revenue This Year
- CHRS $2.47
- NOTE N/A
- Revenue Next Year
- CHRS N/A
- NOTE $4.01
- P/E Ratio
- CHRS N/A
- NOTE N/A
- Revenue Growth
- CHRS 44.19
- NOTE N/A
- 52 Week Low
- CHRS $0.66
- NOTE $0.75
- 52 Week High
- CHRS $2.87
- NOTE $2.27
- Technical
- Relative Strength Index (RSI)
- CHRS 41.91
- NOTE 58.95
- Support Level
- CHRS $1.38
- NOTE $0.98
- Resistance Level
- CHRS $1.60
- NOTE $1.37
- Average True Range (ATR)
- CHRS 0.12
- NOTE 0.16
- MACD
- CHRS -0.03
- NOTE 0.00
- Stochastic Oscillator
- CHRS 1.10
- NOTE 69.64
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About NOTE FiscalNote Holdings Inc.
FiscalNote Holdings Inc is a provider of global policy and market intelligence solutions. Leveraging AI and analytics, it delivers actionable legal and policy insights for businesses, government institutions, and nonprofits. Its suite of products includes FiscalNote Core, CQ Federal, and EU Issue Tracker, facilitating effective policy management and risk mitigation. With expert analysis from FrontierView, Oxford Analytica, and Dragonfly Eye, it offers geopolitical and market intelligence services. Operating as one segment, it generates revenue by integrating policy intelligence into daily operations. Geographically the company generates the majority of its revenue from North America, Europe, Australia, and Asia, with the majority generated from North America.